SKYE
Skye Bioscience·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Decline
Low Cash Short-term Debt Ratio
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SKYE
Skye Bioscience, Inc.
A biopharmaceutical company dedicated to the development of proprietary synthetic cannabinoid derivatives for the treatment of glaucoma.
11250 El Camino Real, Suite 100 San Diego, CA 92130
--
Skye Bioscience, Inc., was incorporated in Nevada on March 16, 2011. The company is a clinical-stage biopharmaceutical company with a mission to pioneer the development of new drugs and unlock the pharmaceutical potential of ECS. Their clinical assets focus on the regulation of CB1, providing new treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration (such as obesity and glaucoma).
Earnings Call
Q1/2025
Estimate EPS-0.29
Actual EPS-0.28
Estimate Revenue--
Actual Revenue--
Skye Bioscience's Q1 2025: Key Contradictions on Trial Extensions, Safety Issues, and Regulatory Interactions
May 19,2025 06:55
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.3
Actual EPS-0.44
Estimate Revenue--
Actual Revenue--
Skye Bioscience's 2025Q2 Earnings Call: Unraveling Key Contradictions in Clinical Trial Insights and Drug Efficacy
Aug 10,2025 05:23
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.32
Actual EPS-0.32
Estimate Revenue--
Actual Revenue0
Skye Bioscience's Q3 2025: Contradictions Emerge on Dose Safety, Monotherapy Efficacy, and Combo Study Potential
Nov 10,2025 11:03
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
SKYE has released its 2025 Q3 earnings. EPS was reported at -0.32, versus the expected -0.32, meeting expectations. The chart below visualizes how SKYE has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
